Literature DB >> 31556100

Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa.

K Navrazhina1,2, J W Frew1, J G Krueger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31556100      PMCID： PMC7195726          DOI： 10.1111/bjd.18556

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  7 in total

1.  IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis.

Authors:  Andrew Johnston; Xianying Xing; Liza Wolterink; Drew H Barnes; ZhiQiang Yin; Laura Reingold; J Michelle Kahlenberg; Paul W Harms; Johann E Gudjonsson
Journal:  J Allergy Clin Immunol       Date:  2016-12-31       Impact factor: 10.793

2.  Apocrine Gland-Rich Skin Has a Non-Inflammatory IL-17-Related Immune Milieu, that Turns to Inflammatory IL-17-Mediated Disease in Hidradenitis Suppurativa.

Authors:  A Jenei; Z Dajnoki; B Medgyesi; K Gáspár; G Béke; Á Kinyó; G Méhes; Z Hendrik; T Dinya; D Törőcsik; C C Zouboulis; E P Prens; T Bíró; A Szegedi; A Kapitány
Journal:  J Invest Dermatol       Date:  2018-10-31       Impact factor: 8.551

3.  IL-17C: A Unique Epithelial Cytokine with Potential for Targeting across the Spectrum of Atopic Dermatitis and Psoriasis.

Authors:  Emma Guttman-Yassky; James G Krueger
Journal:  J Invest Dermatol       Date:  2018-07       Impact factor: 8.551

4.  The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction.

Authors:  Ellen Witte-Händel; Kerstin Wolk; Athanasia Tsaousi; Marie Luise Irmer; Rotraut Mößner; Orr Shomroni; Thomas Lingner; Katrin Witte; Desiree Kunkel; Gabriela Salinas; Stefan Jodl; Nicole Schmidt; Wolfram Sterry; Hans-Dieter Volk; Evangelos J Giamarellos-Bourboulis; Anna Pokrywka; Wolf-Dietrich Döcke; Sylke Schneider-Burrus; Robert Sabat
Journal:  J Invest Dermatol       Date:  2018-12-05       Impact factor: 8.551

5.  IL-17C regulates the innate immune function of epithelial cells in an autocrine manner.

Authors:  Vladimir Ramirez-Carrozzi; Arivazhagan Sambandam; Elizabeth Luis; Zhongua Lin; Surinder Jeet; Justin Lesch; Jason Hackney; Janice Kim; Meijuan Zhou; Joyce Lai; Zora Modrusan; Tao Sai; Wyne Lee; Min Xu; Patrick Caplazi; Lauri Diehl; Jason de Voss; Mercedesz Balazs; Lino Gonzalez; Harinder Singh; Wenjun Ouyang; Rajita Pappu
Journal:  Nat Immunol       Date:  2011-10-12       Impact factor: 25.606

Review 6.  Psoriasis pathogenesis and the development of novel targeted immune therapies.

Authors:  Jason E Hawkes; Tom C Chan; James G Krueger
Journal:  J Allergy Clin Immunol       Date:  2017-09       Impact factor: 10.793

7.  IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model.

Authors:  Andrea Chiricozzi; Kristine E Nograles; Leanne M Johnson-Huang; Judilyn Fuentes-Duculan; Irma Cardinale; Kathleen M Bonifacio; Nicholas Gulati; Hiroshi Mitsui; Emma Guttman-Yassky; Mayte Suárez-Fariñas; James G Krueger
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240
  7 in total
  9 in total

1.  Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.

Authors:  Kristina Navrazhina; John W Frew; David Grand; Samuel C Williams; Hong Hur; Juana Gonzalez; Sandra Garcet; James G Krueger
Journal:  Br J Dermatol       Date:  2022-06-02       Impact factor: 11.113

2.  The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study.

Authors:  John W Frew; Kristina Navrazhina; David Grand; Mary Sullivan-Whalen; Patricia Gilleaudeau; Sandra Garcet; Jonathan Ungar; James G Krueger
Journal:  J Am Acad Dermatol       Date:  2020-05-13       Impact factor: 11.527

Review 3.  IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa.

Authors:  J M Fletcher; B Moran; A Petrasca; C M Smith
Journal:  Clin Exp Immunol       Date:  2020-06-08       Impact factor: 4.330

4.  Autoantibodies Present in Hidradenitis Suppurativa Correlate with Disease Severity and Promote the Release of Proinflammatory Cytokines in Macrophages.

Authors:  Carmelo Carmona-Rivera; Liam J O'Neil; Eduardo Patino-Martinez; William D Shipman; Chengsong Zhu; Quan-Zhen Li; Michelle L Kerns; Leandra A Barnes; Julie A Caffrey; Sewon Kang; Mariana J Kaplan; Ginette A Okoye; Angel S Byrd
Journal:  J Invest Dermatol       Date:  2021-10-01       Impact factor: 8.551

5.  Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa.

Authors:  Kristina Navrazhina; John W Frew; Patricia Gilleaudeau; Mary Sullivan-Whalen; Sandra Garcet; James G Krueger
Journal:  J Allergy Clin Immunol       Date:  2021-02-03       Impact factor: 14.290

6.  In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes.

Authors:  Kristina Navrazhina; Sandra Garcet; Juana Gonzalez; David Grand; John W Frew; James G Krueger
Journal:  J Invest Dermatol       Date:  2021-03-22       Impact factor: 7.590

7.  Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa: A Systematic Review.

Authors:  Samuel Der Sarkissian; Schapoor Hessam; Joslyn S Kirby; Michelle A Lowes; Dillon Mintoff; Haley B Naik; Hans Christian Ring; Nisha Suyien Chandran; John W Frew
Journal:  JAMA Dermatol       Date:  2022-03-01       Impact factor: 11.816

8.  The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris.

Authors:  Kristina Navrazhina; Sandra Garcet; John W Frew; Xiuzhong Zheng; Israel Coats; Emma Guttman-Yassky; James G Krueger
Journal:  J Am Acad Dermatol       Date:  2021-07-30       Impact factor: 11.527

Review 9.  Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.

Authors:  Pim Aarts; Koen Dudink; Allard R J V Vossen; Kelsey R van Straalen; Christine B Ardon; Errol P Prens; Hessel H van der Zee
Journal:  Drugs       Date:  2021-07-20       Impact factor: 9.546
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.